SCHEMBL24364249

SCHEMBL24364249

CC1CCC(c2ccc3c(c2)CC(=O)N3)=NC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.54
PDE4B Q07343 1/20 0.54
PDE4C Q08493 1/20 0.54
PDE4D Q08499 1/20 0.54
PDE3B Q13370 2/20 0.51
PDE3A Q14432 2/20 0.51
GRIA1 P42261 4/20 0.48
CACNG8 Q8WXS5 2/20 0.48
CYP1A2 P05177 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
PGR P06401 4/20 0.45
BRD4 O60885 2/20 0.45
CREBBP Q92793 1/20 0.45
EPHX2 P34913 1/20 0.43
AHR P35869 1/20 0.42
BMPR1B O00238 1/20 0.41
BMPR1A P36894 1/20 0.41
TGFBR1 P36897 1/20 0.41
ACVRL1 P37023 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30470737 0.90 PDE3B (0.53) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL31430298 0.75 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL24365725 0.74 GSK3B (0.47) TGFBR1ACVR1
SCHEMBL31430238 0.73 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL24365805 0.72 PDE3B (0.44) PDE3BPDE3AGRIA1CACNG8
SCHEMBL31145094 0.72 CLK4 (0.49)
SCHEMBL29081863 0.72 JAK2 (0.41) BRD4CREBBPHRH3
SCHEMBL2930091 0.71 PDE3B (0.63) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL29325181 0.71 CRBN (0.40) PDE3BPDE3ACRBN
SCHEMBL25320073 0.70 NOS3 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 PDE4A 1040/4885PDE4B 833/4885PDE4C 930/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 PDE4A 1040/4885PDE4B 833/4885PDE4C 930/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 PDE4A 1040/4885PDE4B 833/4885PDE4C 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.